Zimmer Biomet Holdings Inc (ZBH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zimmer Biomet Holdings Inc (ZBH) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($418.70 Million) by net assets ($12.77 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zimmer Biomet Holdings Inc balance sheet independence to measure how much of total assets are equity-financed.
Zimmer Biomet Holdings Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Zimmer Biomet Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Zimmer Biomet Holdings Inc to evaluate the quality of earnings relative to operating cash generation.
Zimmer Biomet Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zimmer Biomet Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai International Port Group Co Ltd
SHG:600018
|
0.023x |
|
FORTUM OYJ ADR 1/5/EO340
F:FOT0
|
0.043x |
|
Genmab A/S
CO:GMAB
|
0.093x |
|
Brookfield Infrastructure Partners L.P
TO:BIP-UN
|
0.026x |
|
Ke Holdings Inc
NYSE:BEKE
|
0.029x |
|
Grupo Carso S.A.B. de C.V
MX:GCARSOA1
|
-0.002x |
|
KE HOLDINGS SP.ADS/1 CL.A
F:KE8A
|
0.029x |
|
Aluminum Corp of China Ltd
SHG:601600
|
0.065x |
Annual Cash Flow Conversion Efficiency for Zimmer Biomet Holdings Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Zimmer Biomet Holdings Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Zimmer Biomet Holdings Inc (ZBH) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.48 Billion | $1.50 Billion | 0.120x | -5.11% |
| 2023-12-31 | $12.49 Billion | $1.58 Billion | 0.127x | +18.56% |
| 2022-12-31 | $12.03 Billion | $1.28 Billion | 0.107x | -9.75% |
| 2021-12-31 | $12.67 Billion | $1.50 Billion | 0.118x | +19.88% |
| 2020-12-31 | $12.20 Billion | $1.20 Billion | 0.099x | -22.84% |
| 2019-12-31 | $12.39 Billion | $1.59 Billion | 0.128x | -17.43% |
| 2018-12-31 | $11.28 Billion | $1.75 Billion | 0.155x | +14.93% |
| 2017-12-31 | $11.74 Billion | $1.58 Billion | 0.135x | -20.12% |
| 2016-12-31 | $9.67 Billion | $1.63 Billion | 0.169x | +94.92% |
| 2015-12-31 | $9.81 Billion | $849.80 Million | 0.087x | -46.74% |
| 2014-12-31 | $6.52 Billion | $1.06 Billion | 0.163x | +6.36% |
| 2013-12-31 | $6.30 Billion | $963.10 Million | 0.153x | -22.15% |
| 2012-12-31 | $5.87 Billion | $1.15 Billion | 0.196x | -7.99% |
| 2011-12-31 | $5.51 Billion | $1.18 Billion | 0.213x | +3.20% |
| 2010-12-31 | $5.77 Billion | $1.19 Billion | 0.207x | +4.35% |
| 2009-12-31 | $5.64 Billion | $1.12 Billion | 0.198x | +7.94% |
| 2008-12-31 | $5.65 Billion | $1.04 Billion | 0.184x | -7.68% |
| 2007-12-31 | $5.45 Billion | $1.08 Billion | 0.199x | -5.91% |
| 2006-12-31 | $4.92 Billion | $1.04 Billion | 0.211x | +12.77% |
| 2005-12-31 | $4.69 Billion | $878.20 Million | 0.187x | -14.13% |
| 2004-12-31 | $3.95 Billion | $862.20 Million | 0.218x | +38.99% |
| 2003-12-31 | $3.15 Billion | $494.80 Million | 0.157x | -73.87% |
| 2002-12-31 | $366.30 Million | $220.20 Million | 0.601x | -72.46% |
| 2001-12-31 | $78.70 Million | $171.80 Million | 2.183x | +145.16% |
| 2000-12-31 | $261.00 Million | $232.40 Million | 0.890x | +93.42% |
| 1999-12-31 | $391.00 Million | $180.00 Million | 0.460x | -- |
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skul… Read more